BioCentury
ARTICLE | Targets & Mechanisms

Solid hopes for T cell bispecifics

Will next-generation T cell bispecifics find their place in solid tumors?

May 4, 2018 2:56 AM UTC

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors.

T cell bispecific antibodies bring activated T cells into proximity with tumor cells to facilitate tumor killing, similar to the way CARs mobilize T cells to fight cancers. First-generation platforms have a CD3-binding domain linked to a tumor antigen-binding domain; next-generation platforms add a third domain to promote protein stability. ...